Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease (European Journal of Drug Metabolism and Pharmacokinetics, (2021), 46, 2, (277-287), 10.1007/s13318-020-00669-7)

Christopher M. Rubino, Nikolas J. Onufrak, Jakko van Ingen, David E. Griffith, Sujata M. Bhavnani, Dayton W. Yuen, Kevin C. Mange, Kevin L. Winthrop

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a few errors. The correct information is given below: Page 281, 1st paragraph, 2nd sentence, which previously read: The serum samples in TR02-112 were clustered in two primary windows—0–4 h and 12–24 h postdose (Fig. 1). Should read: The serum samples in TR02-112 were clustered in two primary windows—0–4 h and 12–24 h postdose (Fig. 2).Figure 2: The 24- and 48-hour labels on the x-axis in Figure 2 were transposed. The corrected version of Fig. 2 is given below: The corrected version of supplementary file is updated here.

Original languageEnglish (US)
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Population Pharmacokinetic Evaluation of Amikacin Liposome Inhalation Suspension in Patients with Treatment‑Refractory Nontuberculous Mycobacterial Lung Disease (European Journal of Drug Metabolism and Pharmacokinetics, (2021), 46, 2, (277-287), 10.1007/s13318-020-00669-7)'. Together they form a unique fingerprint.

Cite this